Compare Blue Owl Capital Inc. Class A Common Stock (OWL) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blue Owl Capital Inc. Class A Common Stock vs Philip Morris International Inc. — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.65 (market cap $6.01B), while Philip Morris International Inc. trades at $206.79 (market cap $320.42B). The key difference: Philip Morris International Inc. is far larger — about 53.3× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (10.35%). Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and Philip Morris International Inc. for 85 Days on average.
| OWL | PM | |
|---|---|---|
Market Cap | $6.01B | $320.42B |
Volume | 24,327,195 | 4,295,645 |
Sector | Financials | Consumer Staples |
52-Week High | $17.17 | $205.58 |
52-Week Low | $8.23 | $144.33 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $10.19B | $363.53B |
Dividend Yield | 10.35% | 3.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Philip Morris International (PM) trades at $199.29, down 1.34% on the day, with strong earnings momentum after beating Q1 and Q2 2026 EPS estimates. The company shows robust fundamentals with 2025 revenue of $40.65B and net income margin of 25.56%, though valuation ratios appear elevated. Technical indicators show a bullish moving average trend but overbought RSI signals, with key support at $199. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now representing over 40% of revenue.
PM's outlook remains positive with analyst consensus price target of $212.17 (6.5% upside) and 68% buy ratings. Growth is driven by smoke-free product adoption and international expansion, but risks include regulatory pressures, high debt levels, and premium valuation. The stock offers dividend income with recent $1.60 payout, supporting total return potential for investors comfortable with tobacco sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
